Incanthera PLC (AQSE:INC) is close to signing a commercial agreement with a global direct-to-consumer marketing group to launch its Skin + CELL skincare range.
The London-listed company, which develops dermatology and oncology technologies, said on Thursday it expected to finalise the agreement in the next week.
The deal will see the unnamed agency promote the products through its platform using influencers and social media, in return for a royalty fee based on sales.
Under the planned arrangement, customers will place orders via a dedicated Skin + CELL website operated by Incanthera.
Fulfilment will be managed by a third-party logistics provider in Switzerland, where the company holds 100,000 finished units of stock across the face, body and hand care range. The product launch is targeted for the third quarter of 2025.
A tie-up with Marionnaud, a Swiss and Austrian retailer owned by the A.S. Watson Group, will not now go ahead.
Thursday's announcement follows Incanthera’s confirmation in March that it had resolved a patent infringement dispute related to the Skin + CELL formulation and was pursuing several potential commercial routes to market.
The decision to pursue a direct-to-consumer model, the company said, would allow it to retain control over brand positioning, pricing and marketing strategy, while providing access to a wider customer base and higher profit margins.
It also expects to benefit from real-time payments and improved cash flow, with all revenue from the sales flowing directly to the company.
Incanthera said it anticipates selling its entire current stock within the current financial year.